The abstract is read at the publisher; the summary is JClub's.
In a randomized phase 2 study of multiple myeloma with advanced renal failure, pomalidomide plus bortezomib and dexamethasone improves myeloma control and increases renal function after four cycles.
- Why it matters: First-line treatment selection is difficult when multiple myeloma co-occurs with advanced kidney impairment, because achieving hematologic response while preserving renal function is hard.
- What they did: Xiao and colleagues tested a pomalidomide–bortezomib–dexamethasone triplet in a randomized phase 2 design, assessing myeloma disease control and renal function after four cycles.
- The result: The regimen is linked to better disease control and improved renal function at four cycles, supporting renal rescue as a treatment-relevant goal in this setting.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.